Subject: Citigroup Funding 12% ELKS linked to Celgene Corporation

Background Information on the Security

As more fully set forth in the Prospectus Supplement (333-157386), the Citigroup Funding 12% Equity Linked Security ELKS based upon the common stock of Celgene Corporation (“Celgene”) were issued at $10.00 and mature on April 21, 2010.

Equity Linked Securities, or ELKS, are equity-linked investments that offer current income as well as limited protection against the decline in the price of the common stock on which the ELKS are based. The ELKS based upon the common stock of Celgene have a maturity of approximately one year and are issued by Citigroup Funding Inc. The ELKS will pay a semi-annual coupon equal to approximately 10 to 13% per annum. As described in the prospectus, at maturity, investors will receive for each $10 ELKS: (1) a fixed number of shares of the Underlying Equity equal to the equity ratio (or, if the investor exercises his or her cash election right, the cash value of those shares based on the closing price of the Underlying Equity on the valuation date), if the trading price of the Underlying Equity any time after the pricing date up to and including the valuation date (whether intra-day or at the close of trading on any day) declines by approximately 40% (to be determined on the pricing date) or more, or (2) $10 in cash.

The ELKS are subject to the credit risk of Citigroup Inc., Citigroup Funding’s parent company and the guarantor of any payments due on the ELKS.

Holders of ELKS will not be entitled to any rights with respect to Celgene common stock (including, without limitation, voting rights or rights to receive dividends or other distributions in respect thereof) prior to receiving shares of Celgene common stock at maturity, if applicable.

The issuer of the Underlying Equity is not involved in the offering of the ELKS and has no obligations relating to the ELKS. Holders of the ELKS will not be entitled to any rights with respect to Celgene common stock (including, without limitation, voting rights or rights to receive dividends or other distributions in respect thereof) prior to receiving shares of common stock at maturity, if applicable.

The ELKS are a series of unsecured senior debt securities issued by Citigroup Funding. Any payments due on the ELKS are fully and unconditionally guaranteed by Citigroup.
Inc., Citigroup Funding’s parent company. The ELKS will rank equally with all other unsecured and unsubordinated debt of Citigroup Funding and any payments due under the ELKS will rank equally with all other unsecured and unsubordinated debt of Citigroup Inc. The return of the principal amount of an investor’s investment in the ELKS at maturity is not guaranteed.

Citigroup Investment Research or other affiliates of Citigroup Funding may publish research reports or otherwise express opinions or provide recommendations from time to time regarding Celgene common stock or other matters that may influence the price of Celgene common stock and, therefore, the value of the ELKS. Any research, opinion or recommendation expressed by Citigroup Investment Research or other Citigroup Funding affiliates may not be consistent with purchasing, holding or selling the ELKS.

Other factors, many of which are beyond the issuer’s control, will also influence the value of the ELKS. One can expect that generally the market price of the underlying common stock shares on any day will affect the value of the ELKS more than any other single factor. Other factors that may influence the value of the ELKS include: supply and demand for the ELKS, volatility of the underlying stock, interest rates, economic, financial, political and regulatory or judicial events. In addition, the time remaining to maturity and the credit worthiness of Citigroup Funding Inc. may influence the pricing of the ELKS.

For additional information regarding the Securities, please consult the pricing supplement.

**Exchange Rules Applicable to Trading in the Security**

The Shares are considered equity securities, thus rendering trading in the Shares subject to the Exchange's existing rules governing the trading of equity securities.

**Trading Hours**

Trading in the Shares on ISE is on a UTP basis and is subject to ISE equity trading rules. The Shares will trade from 8:00 a.m. until 8:00 p.m. Eastern Time. Equity EAMs trading the Shares during the Extended Market Sessions are exposed to the risk of the lack of the calculation or dissemination of underlying index value or intraday indicative value ("IIV"). For certain derivative securities products, an updated underlying index value or IIV may not be calculated or publicly disseminated in the Extended Market hours. Since the underlying index value and IIV are not calculated or widely disseminated during Extended Market hours, an investor who is unable to calculate implied values for certain derivative securities products during Extended Market hours may be at a disadvantage to market professionals.

**Trading Halts**

ISE will halt trading in the Shares in accordance with ISE Rule 2101(a)(2)(iii). The grounds for a halt under this Rule include a halt by the primary market because it stops trading the Shares and/or a halt because dissemination of the IIV or applicable currency spot price has ceased, or a halt for other regulatory reasons. In addition, ISE will stop trading the Shares if the primary market de-lists the Shares.
**Delivery of a Prospectus**

Pursuant to federal securities laws, investors purchasing Shares must receive a prospectus prior to or concurrently with the confirmation of a transaction. Investors purchasing Shares directly from the Fund (by delivery of the Deposit Amount) must also receive a prospectus.

Prospectuses may be obtained through the Distributor or on the Fund’s website. The Prospectus does not contain all of the information set forth in the registration statement (including the exhibits to the registration statement), parts of which have been omitted in accordance with the rules and regulations of the SEC. For further information about the Fund, please refer to the Trust’s registration statement.

*This Regulatory Information Circular is not a statutory Prospectus. Equity EAMs should consult the Trust’s Registration Statement, SAI, Prospectus and the Fund’s website for relevant information.*
### Appendix A

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Fund Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELU</td>
<td>Citigroup Funding 12% Equity Linked Security ELKS Based Upon the Common Stock of Celgene Corporation Due May 26, 2010</td>
</tr>
</tbody>
</table>